Adding the PD-L1 inhibitor atezolizumab to first-line platinum-based chemotherapy significantly prolonged progression-free survival (PFS) compared with chemotherapy alone in patients with metastatic urothelial carcinoma (mUC), according to the IMvigor130* study presented at the ESMO Congress 2019.
The novel antibody-drug conjugate enfortumab vedotin showed promising clinical activity in patients with advanced and metastatic urothelial cancer for whom there is a high unmet need, according to the EV-201 study presented at the ASCO 2019 Meeting.
Sacituzumab govitecan, a novel investigational antibody-drug conjugate, showed clinical activity in patients with metastatic urothelial carcinoma (mUC) who had progressed following standard therapy, including treatment with checkpoint inhibitors, according to an early study presented at GUCS 2019.
The 2018 Nobel Prize in Medicine is awarded to two researchers who discovered that the cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) proteins limit the ability of T cells to attack cancer cells. Their discovery led to the development of immune checkpoint inhibitors that have revolutionized cancer treatment.
Administering intravesical gemcitabine immediately after tumour resection leads to a significant reduction in the long-term risk of recurrence in patients with suspected low-grade nonmuscle-invasive urothelial cancer, a study has shown.
Blue light cystoscopy delivers increased detection rates of carcinoma in-situ and papillary lesions, leading to upstaging or upgrading in a substantial proportion of patients, compared with a cystoscopic examination utilizing a white light, a study has shown.
Patients with urologic cancers are more likely to attempt suicide, highlighting the need for increased psychiatric intervention for these patients at an earlier stage, according to findings presented at the European Association of Urology (EAU) 2018 Congress.
Women who undergo radical cystectomy for bladder cancer are more likely to have worse outcomes, including disease-free survival, cancer-specific survival and overall survival, compared with their male counterparts, a study reports.
Office-based blue light flexible cystoscopy significantly improves detection of patients with recurrent bladder cancer and is safe when performed for surveillance compared white light flexible cystoscopy, as shown in a recent study.
Tivozanib as third- or fourth-line therapy improves progression-free survival (PFS) compared with sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have received ≥2 previous systemic treatments, according to results of the phase III, randomized, controlled TIVO-3 trial.